| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Carl L. G. Hansen is Chief Executive Officer at ABCL. Carl L. G. Hansen's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $10.9M at current prices.
The ABCL filings lean toward selling, a net 6,000,000 shares.
Carl L. G. Hansen has 19 Form 4 filings on record from June 2021 to January 2026, all as Chief Executive Officer at AbCellera Biologics (ABCL), 2021–2026.
The 20 reported transactions were 13 option exercises, 5 option or other derivative awards and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $144.8M.
The only open-market sale was 6,000,000 shares of ABCL at an average $24.13 on June 9, 2021, about $144.8M. Twelve months later ABCL was down 65%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2021 | ABCL Abcellera Biologics Inc. | Chief Executive Officer | Sell | 6,000,000 | $24.13 | $144,770,322.60 | -96.3% | -20.5% | -64.8% |